EATG co-signed a letter calling on Gilead to announce and expand its commitment to register long-acting lenacapavir for broad use in low- and middle-income countries.
“We call on Gilead to urgently address this inadequate regulatory agenda that will harm access during its two-year period as a sole supplier and further hobble efforts to register generic equivalents in the future.”
Access the full letter here.
Source : Public Citizen
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Real-world data support switch to doravirine-based ART: HIV-1 control and QOL
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.